Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04−1.16 (-36.25%)
Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –
Kyntra Bio total assets
Total assets on the balance sheet at the end of each period.
Kyntra Bio's total assets was $101.08M at Jun 30, 2026. For fiscal 2025 it was $119.59M, down 44.3% from the year before. Over ten years it grew -12.8% a year on average. The highest annual figure on record is $898.65M in fiscal 2017.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.59M | -44.3% |
| FY2024 | Dec 31, 2024 | $214.53M | -49.3% |
| FY2023 | Dec 31, 2023 | $423.53M | -30.6% |
| FY2022 | Dec 31, 2022 | $610.09M | -21.2% |
| FY2021 | Dec 31, 2021 | $773.82M | -6.4% |
| FY2020 | Dec 31, 2020 | $826.84M | -3.6% |
| FY2019 | Dec 31, 2019 | $857.40M | -2.6% |
| FY2018 | Dec 31, 2018 | $880.60M | -2.0% |
| FY2017 | Dec 31, 2017 | $898.65M | +91.4% |
| FY2016 | Dec 31, 2016 | $469.55M | -0.2% |
| FY2015 | Dec 31, 2015 | $470.57M | -2.7% |
| FY2014 | Dec 31, 2014 | $483.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $101.08M | -43.2% |
| Q1 FY2026 | Mar 31, 2026 | $109.63M | -33.6% |
| Q4 FY2025 | Dec 31, 2025 | $119.59M | -44.3% |
| Q3 FY2025 | Sep 30, 2025 | $137.01M | -48.2% |
| Q2 FY2025 | Jun 30, 2025 | $178.06M | -39.3% |
| Q1 FY2025 | Mar 31, 2025 | $165.21M | -54.8% |
| Q4 FY2024 | Dec 31, 2024 | $214.53M | -49.3% |
| Q3 FY2024 | Sep 30, 2024 | $264.42M | -42.6% |
| Q2 FY2024 | Jun 30, 2024 | $293.20M | -43.1% |
| Q1 FY2024 | Mar 31, 2024 | $365.87M | -32.1% |
| Q4 FY2023 | Dec 31, 2023 | $423.53M | -30.6% |
| Q3 FY2023 | Sep 30, 2023 | $460.43M | -24.4% |
| Q2 FY2023 | Jun 30, 2023 | $515.13M | -25.0% |
| Q1 FY2023 | Mar 31, 2023 | $538.54M | -27.8% |
| Q4 FY2022 | Dec 31, 2022 | $610.09M | -21.2% |
| Q3 FY2022 | Sep 30, 2022 | $608.84M | -28.4% |
| Q2 FY2022 | Jun 30, 2022 | $686.79M | -15.1% |
| Q1 FY2022 | Mar 31, 2022 | $745.93M | -5.3% |
| Q4 FY2021 | Dec 31, 2021 | $773.82M | -6.4% |
| Q3 FY2021 | Sep 30, 2021 | $850.51M | +4.7% |
| Q2 FY2021 | Jun 30, 2021 | $808.62M | +0.1% |
| Q1 FY2021 | Mar 31, 2021 | $787.30M | -4.5% |
| Q4 FY2020 | Dec 31, 2020 | $826.84M | -3.6% |
| Q3 FY2020 | Sep 30, 2020 | $812.02M | -9.2% |
| Q2 FY2020 | Jun 30, 2020 | $807.68M | -11.7% |
| Q1 FY2020 | Mar 31, 2020 | $824.38M | +1.5% |
| Q4 FY2019 | Dec 31, 2019 | $857.40M | -2.6% |
| Q3 FY2019 | Sep 30, 2019 | $893.96M | +4.5% |
| Q2 FY2019 | Jun 30, 2019 | $915.07M | +5.2% |
| Q1 FY2019 | Mar 31, 2019 | $812.40M | -6.4% |
| Q4 FY2018 | Dec 31, 2018 | $880.60M | -2.0% |
| Q3 FY2018 | Sep 30, 2018 | $855.64M | -4.4% |
| Q2 FY2018 | Jun 30, 2018 | $869.92M | +60.3% |
| Q1 FY2018 | Mar 31, 2018 | $867.61M | +96.4% |
| Q4 FY2017 | Dec 31, 2017 | $898.65M | +91.4% |
| Q3 FY2017 | Sep 30, 2017 | $894.89M | +84.1% |
| Q2 FY2017 | Jun 30, 2017 | $542.64M | – |
| Q1 FY2017 | Mar 31, 2017 | $441.76M | – |
| Q4 FY2016 | Dec 31, 2016 | $469.55M | – |
| Q3 FY2016 | Sep 30, 2016 | $486.21M | – |
See a number that looks wrong?